Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
|
|
- Spencer Matthews
- 6 years ago
- Views:
Transcription
1 Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
2 Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2
3 Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Synta Pharmaceuticals Corp (Synta) is a pharmaceutical company that discovers, develops and commercializes novel pharmaceutical products for the treatment of cancer and other severe medical conditions. It has a unique chemical compound, an integrated discovery engine and a diverse pipeline of clinical and preclinical stage drug candidates. The company has a clinical-stage drug candidate (ganetespib) in cancer and a novel, proprietary small molecule cancer drug development program, the HDC program. Ganetespib is a novel, potent, small molecule inhibitor of Hsp90, a molecular chaperone required for the proper folding and activation of various cancer-promoting proteins. Synta is headquartered in Lexington, Massachusetts, the US. Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. 3
4 - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDPH82226D Number of Pages : 41 Report Format : PDF Publisher Information : 4
5 5
6 Table Of Contents for Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Table of Contents Table of Contents 2List of Tables 3List of Figures 4Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 11Partnerships 11Ergomed Enters Into Co-Development Agreement with Synta 11Multiple Myeloma Research Foundation Enters Into Collaboration With Synta Pharma For Ganetespib 13Merger 15Madrigal Pharma and Synta Pharma Merges 15Licensing Agreements 17Synta Pharma Extends Licensing Agreement With Roche 17Synta Pharma Extends Its Licensing Agreement With Roche 18Equity Offering 19Synta Pharma Raises USD44.3 Million in Public Offering of Shares 19Synta Pharma Announces Private Placement Of Shares For Us$5 Million 21Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 22Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 24Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 25Synta Pharma Completes Private Placement Of Shares For US$26 Million 27Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 29Synta Pharma Completes Registered Direct Offering For US$35.2 Million 31Synta Pharma Completes Private Placement Of US$5 Million 33Synta Pharma Announces Private Placement Of US$35 Million 34Synta Pharma Announces Exercise Of Underwriter s Over Allotment Option 36Synta Pharmaceuticals Corp - Key Competitors 38Key Employees 39Locations And Subsidiaries 40Head Office 40Other Locations & Subsidiaries 40Appendix 41Methodology 41About GlobalData 41Contact Us 41Disclaimer 41 6
7 List Of Tables in Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Tables Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD Synta Pharmaceuticals Corp, Deals By Therapy Area, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD Ergomed Enters Into Co-Development Agreement with Synta 11 Multiple Myeloma Research Foundation Enters Into Collaboration With Synta Pharma For Ganetespib 13 Madrigal Pharma and Synta Pharma Merges 15 Synta Pharma Extends Licensing Agreement With Roche 17 Synta Pharma Extends Its Licensing Agreement With Roche 18 Synta Pharma Raises USD44.3 Million in Public Offering of Shares 19 Synta Pharma Announces Private Placement Of Shares For Us$5 Million 21 Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 22 Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 24 Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 25 Synta Pharma Completes Private Placement Of Shares For US$26 Million 27 Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 29 Synta Pharma Completes Registered Direct Offering For US$35.2 Million 31 Synta Pharma Completes Private Placement Of US$5 Million 33 Synta Pharma Announces Private Placement Of US$35 Million 34 Synta Pharma Announces Exercise Of Underwriter s Over Allotment Option 36 Synta Pharmaceuticals Corp, Key Competitors 38 Synta Pharmaceuticals Corp, Key Employees 39 Synta Pharmaceuticals Corp, Other Locations 40 Synta Pharmaceuticals Corp, Subsidiaries 40 7
8 List Of Figures, Charts and Diagrams in Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Figures Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD Synta Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD
9 How to Buy... Synta Pharmaceuticals Corp (SNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 9
ConvaTec Healthcare B Sarl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
ConvaTec Healthcare B Sarl - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Healthcare B Sarl - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationCairn Energy PLC (CNE) - Power - Deals and Alliances Profile
Cairn Energy PLC (CNE) - Power - Deals and Alliances Profile Cairn Energy PLC (CNE) - Power - Deals and Alliances Profile Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationLondon Stock Exchange Group plc (LSE) - Financial and Strategic SWOT Analysis Review
London Stock Exchange Group plc (LSE) - Financial and Strategic SWOT Analysis Review London Stock Exchange Group plc (LSE) - Financial and Strategic SWOT Analysis Review Sector Publishing Intelligence
More informationTAM S.A. (formerly TAM-Companhia de Investimentos em Transportes) Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional market research reports and company analyses for over 7 years. Our experienced staff team are
More informationSamling Global Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Samling Global Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Samling Global Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Sector
More informationSvenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report
Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report The Business Research Store is run by Sector Publishing Intelligence
More informationKayne Anderson Capital Advisors L.P. - Oil & Gas - Investment Profile
Kayne Anderson Capital Advisors L.P. - Oil & Gas - Investment Profile Kayne Anderson Capital Advisors L.P. - Oil & Gas - Investment Profile Sector Publishing Intelligence Limited (SPi) has been marketing
More informationEOG Resources, Inc. (EOG) - Oil & Gas - Deals and Alliances Profile
Report Information More information from: https://www.wiseguyreports.com/reports/29304-eog-resources-inc-eog-oil-gas-deals-and-alliancesprofile EOG Resources, Inc. (EOG) - Oil & Gas - Deals and Alliances
More informationGlobal Telemedicine Market Outlook 2022
Global Telemedicine Market Outlook 2022 Global Telemedicine Market Outlook 2022 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationMedical Alert Systems/Personal Emergency Response System (PERS) Market by Type (Landline PERS, Mobile PERS (MPERS), Standalone PERS), by End- User
Medical Alert Systems/Personal Emergency Response System (PERS) Market by Type (Landline PERS, Mobile PERS (MPERS), Standalone PERS), by End- User (Home-Based, Senior Living Facilities, and Assisted Living
More informationRailroads in Germany - Industry and Country Analysis
Railroads in Germany - Industry and Country Analysis Railroads in Germany - Industry and Country Analysis Sector Publishing Intelligence Limited (SPi) has been marketing business and market research reports
More information2020 Foresight Report: The Impact of Anti-Money Laundering Regulations on Wealth Management
2020 Foresight Report: The Impact of Anti-Money Laundering Regulations on Wealth Management 2020 Foresight Report: The Impact of Anti- Money Laundering Regulations on Wealth Management Sector Publishing
More informationChemical Biological Radiological Nuclear and Explosives (CBRNE) Detection Equipment Market - By System (Radiation Detectors, Spectrometers,
Chemical Biological Radiological Nuclear and Explosives (CBRNE) Detection Equipment Market - By System (Radiation Detectors, Spectrometers, Simulators, Others); By Detection (Chemical, Biological and Others);
More informationPower Quarterly Deals Analysis: M&A and Investment Trends - Q4 2017
Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2017 #1654058 $1500 75 pages In Stock Report Description Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2017 Summary GlobalDatas
More informationApparel Retail in Switzerland
Sector Publishing Intelligence Limited (SPi) has been marketing business and market research reports from selected publishers for over five years. SPi offers a personal service to our customers with dedicated
More information(NASDAQ: SNTA) Synta Pharmaceuticals. Bullish. Investment Highlights
(NASDAQ: SNTA) Bullish Overview Recent Price $5.46 52 Week Range $3.70 - $11.29 1 Month Range $5.06 - $6.58 Avg Daily Volume 2078247.0 PE Ratio 0.0 Earnings Per Share Year EPS 2014(E) $-1.249 Capitalization
More informationMeasuring the return from pharmaceutical innovation 2017 Methodology
Measuring the return from pharmaceutical innovation 2017 Methodology Contents Introduction 01 Methodology 02 Original cohort 03 Extension cohort 03 Assets evaluated 03 Methodology amendments and restatements
More informationAstex Pharmaceuticals Reports 2013 Second Quarter Financial Results
News Release Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results SGI-110 clinical data presented at EHA for Phase 1 MDS patients Second quarter royalty revenue increased 15% to $16.6 million
More informationCardinal Health, Inc. - Financial and Strategic SWOT Analysis Review
Publication Date: FEB 2013 7000 Cardinal Place Phone Revenue Dublin, OH Fax Net Profit 43017 Website Employees United States Exchange Industry Company Overview Cardinal Health, Inc. (Cardinal Health) is
More informationGalapagos reports record revenues and increased profitability in 2010
Regulated information 4 March 2011 Galapagos reports record revenues and increased profitability in 2010 Revenues 136.6 M (+29%) Net profit 4.4 M ( 09: 3.0 M) Operating profit 1.0 M ( 09: 1.7 M) Year end
More informationLigand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009 Ligand to Acquire Metabasis for Cash and Contingent Value Rights Ligand to Gain Fully Funded Partnership with Roche for Hepatitis and Promising Development-Stage Programs SAN DIEGO-- Ligand
More information2Q 19 Earnings Call Presentation. February 5, 2019
2Q 19 Earnings Call Presentation February 5, 2019 Agenda John Chiminski, Chair & Chief Executive Officer 2Q 19 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Business Update by Segment
More informationMolecular Partners' IPO bookbuilding resumes with support from Allergan as well as other anchor investors
This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular, this release and the information
More informationHeidelberg Pharma announces financial figures for fiscal year 2017 and provides business update
PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update Financials in line with guidance on the back of positive revenue performance Corporate actions
More informationOvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company Transaction to Advance Millendo s Compelling Pipeline of Late Stage Programs for Orphan Endocrine Diseases
More informationPremier Oil plc (PMO) - Financial and Strategic SWOT Analysis Review. Reference Code: GDGE1287FSA Publication Date: NOV 2014.
Publication Date: NOV 2014 Company Overview Phone Fax Website Exchange Revenue Net Profit Employees Industry Premier Oil plc (Premier Oil) is an independent upstream energy company specializing in the
More informationINDUSTRY. Blue Book. Drug & Device Outsourcing 3Q16. Segment: Discovery CROSSTREE C A P I T A L P A R T N E R S
INDUSTRY Blue Book Drug & Device Outsourcing 3Q16 Segment: CROSSTREE C A P I T A L P A R T N E R S Introduction Crosstree Capital Partners provides mergers and acquisitions and financing advisory services
More informationHow to value your start-up Dr. Patrik Frei January 2016 San Francisco
How to value your start-up Dr. Patrik Frei January 2016 San Francisco Overview Introduction to Valuation Valuation of start-up companies Valuation of a therapeutic Product Q & A 2 Venture Valuation Mission
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly
More informationCatalent, Inc. Jefferies Global Healthcare Conference. June 9, DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.
Catalent, Inc. Jefferies Global Healthcare Conference June 9, 2016 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied. Disclaimer Statement Forward-Looking Statements This
More information4Q 18 Earnings Call Presentation. August 28, 2018
4Q 18 Earnings Call Presentation August 28, 2018 Agenda John Chiminski, Chair & Chief Executive Officer 4Q 18 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Segment Reporting Structure
More informationCelgene Reports First Quarter 2009 Operating and Financial Results. SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, Celgene Corporation (NASDAQ: CELG):
Celgene Reports First Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009-- Celgene Corporation (NASDAQ: CELG): REVLIMID Continues Gains in Multiple Myeloma Both in
More informationCannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook.
Cannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook. Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is engaged in the development of Personalized Anti- Cancer treatments.
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationRoche: Innovation & profitable growth Lazard Conference 15 November 2011
Roche: Innovation & profitable growth Lazard Conference 15 November 2011 Thomas Kudsk Larsen, Head of Investor Relations North America Eka Kortkhonjia, Investor Relations Officer This presentation contains
More informationAerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update November 6, 2018 Conference Call and Webcast Today, November 6 th, at 5:00 p.m. ET DURHAM, N.C.--(BUSINESS
More informationIFRS industry insights
IFRS Global Office March 2013 IFRS industry insights Joint arrangements in the life sciences industry IFRS 11 does not change the definition of a joint arrangement under IAS 31 as being an arrangement
More informationXOMA Reports First Quarter 2006 Results *********************************************************************
News Release Paul Goodson Investor Relations Tel: (510) 204-7270 XOMA Reports First Quarter 2006 Results ********************************************************************* Berkeley, CA May 10, 2006
More informationAntibody Targeted Amanitin Conjugates
ANNUAL REPORT 2016 Antibody Targeted Amanitin Conjugates Making the compound Amanitin available for cancer therapies Key figures 2016 1 000 2015 1 000 Change in % Earnings Sales revenue 1,362 2,284 (40
More informationSAMPLE. Exterran Holdings, Inc. Analysis Across the Oil and Gas Value Chain Report. Reference Code: GDGE55152AAD. Publication Date: NOV 2012
Exterran Holdings, Inc. Analysis Across the Oil and Gas Value Publication Date: NOV 2012 Page 1 Table of Contents Table of Contents... 2 List of Tables... 3 Company Snapshot... 4 Company Overview... 4
More informationBETTER PARTNERSHIPS: THE ALTERNATIVE TO M&A?
BETTER PARTNERSHIPS: THE ALTERNATIVE TO M&A? Novasecta: Specialist Pharmaceutical Management Consulting In a world of low-cost capital and investor pressure for earnings growth, M&A is still top of the
More informationJUBILANT LIFE SCIENCES Q4/FY2017 RESULTS
PRESS RELEASE Noida, Tuesday, May 23, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4/FY2017 RESULTS JUBILANT REPORTS
More informationCelgene Corporation. In 2001, Celgene advanced its programs for. the processes involved in abnormal cell growth
A n n u a l R e p o r t 2 0 0 1 An Integrated Biopharmaceutical Company Focused on Discovering, Developing and Commercializing Innovative Therapies to Treat Cancer and Inflammation through Gene and Protein
More informationG L P G I N T E R I M R E P O R T I N T E R I M R E P O R T
G L P G 2 0 0 7 I N T E R I M R E P O R T I N T E R I M R E P O R T TABLE OF CONTENTS LETTER TO OUR SHAREHOLDERS.... 3 UNAUDITED CONSOLIDATED INCOME STATEMENT FOR THE SIX MONTHS ENDED 30 JUNE... 5 UNAUDITED
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationCatalent to Acquire Cook Pharmica. September 19, 2017
Catalent to Acquire Cook Pharmica September 19, 2017 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements, including concerning the closing
More information3M Reports Record 2007 Sales and Earnings
Publicado em 3M News United States (https://news.3m.com) on 1/29/08 6:30 am CST 3M Reports Record 2007 Sales and Earnings Release Date: terça-feira, Janeiro 29, 2008 6:30 am CST Terms: Company (English)
More information1 st Quarter 2008 Revenue
1 st Quarter 2008 Q1 2007 Q1 2008 08/07 as published 08/07 Gas and Services revenue 2 452 2 649 +8.0% +9.1% Engineering & Construction 86 189 +119.9% +12.5% Other Activities 253 253 +0.2% +1.5% Total revenue
More informationSmall-Cap Research. Stellar Biotech (SBOT-NASDAQ) SBOT: JV With Neovacs Offers Full Product Life Cycle Opportunity OUTLOOK SUMMARY DATA
Small-Cap Research January 26, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Stellar Biotech (SBOT-NASDAQ) SBOT: JV With Neovacs Offers
More informationHeidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018 Exclusive research agreement signed with Magenta for the development of Antibody Targeted Amanitin Conjugates License
More informationNanogen Epoch Biosciences Merger Frequently Asked Questions
Filed by Nanogen, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Epoch Biosciences, Inc.
More informationCBI - 10th Life Sciences Accounting and Reporting Congress. March 18, 2014
CBI 0th Life Sciences Accounting and Reporting Congress March 8, 204 Introductions Brent Sabatini Director Technical Accounting & Controls Prateep Menon, CFA Principal Life Sciences Advisory Services One
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationContract Manufacturing Industry Outlook. Jim Miller, President PharmSource, A GlobalData Company
Contract Manufacturing Industry Outlook Jim Miller, President PharmSource, A GlobalData Company GlobalData: Who we are 2 GlobalData is a leading data & insights solution provider who, for over 40 years,
More informationTopotarget and BioAlliance Pharma enter into merger agreement to create a leading orphan oncology company
To NASDAQ OMX Copenhagen A/S Announcement no. 06-14 / Copenhagen, April 16, 2014 Topotarget A/S Symbion Fruebjergvej 3 DK-2100 Copenhagen Denmark T: +45 39 17 83 92 E: enquiries@topotarget.com Comp reg.:
More informationFEEL BETTER. CONNECTED.
FEEL BETTER. CONNECTED. Connected across pharmacy and medical. To take you further. Katy Wong, RPh, MBA Vice President, Producer Relations Cigna Pharmacy Management Offered by: Cigna Health and Life Insurance
More informationValeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances
More informationCANNASAT THERAPEUTICS INC.
CANNASAT THERAPEUTICS INC. For the year ended December 31, 2006 All amounts are expressed in Canadian (CDN) dollars unless otherwise indicated MANAGEMENT DISCUSSION AND ANALYSIS OF OPERATING RESULTS AND
More informationRanbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec 14 Sales Rs.81,778 Mn
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationMerck & Co., Inc Galloping Hill Road Kenilworth, N.J (908)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period
More informationPieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON,
More informationLonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland
News Release Lonza Reports Strong Momentum with Organic Growth of 8% Sales and 11% CORE EBITDA in H1 2018 Double-Digit Organic Sales Growth for Businesses Along the Healthcare Continuum Outperformance
More informationSareum Holdings plc. Paper on lead candidate CHK1 published in high-impact journal. Update. 23 July 2015 HYBRIDAN LLP
Update 23 July 2015 Key Statistics Code : SAR Listing : AIM Sector : Pharmaceuticals & Biotech Market Cap FD : 6m Shares in issue FD : 2,487.4m Current Price : 0.245 12 mnth High/Low : 0.6p/0.205p Stock
More informationFinancial Results of Astellas for the First Nine Months of FY2017
Contact: Corporate Communications, Astellas Pharma Inc. TEL +81-3-3244-3201 January 31, 2018 Financial Results of Astellas for the First Nine Months of FY2017 Japan, January 31, 2018 Astellas Pharma Inc.
More informationKite Pharma Reports First Quarter 2015 Financial Results
May 15, 2015 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company
More informationManagement s Discussion and Analysis of Financial Condition and Results of Operations of Profound Medical Corp. for the Year Ended December 31, 2015
Management s Discussion and Analysis of Financial Condition and Results of Operations of Profound Medical Corp. for the Year Ended December 31, 2015 The following Management s Discussion and Analysis (
More informationEstimate of Medicare Part D Costs After Accounting for Manufacturer Rebates
October 2016 Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates A Study of Original Branded Products in the U.S. $ Introduction The cost of medicines in the U.S. has been the subject
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationManagement Discussion and Analysis
Management Discussion and Analysis Macquarie Group Year ended 31 March 2018 MACQUARIE GROUP LIMITED ACN 122 169 279 Notice to readers The purpose of this report is to provide information supplementary
More informationMoleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017
August 14, 2017 Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017 HOUSTON, TX -- (Marketwired) -- 08/14/17 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin"
More informationPJT Partners Inc. June 22, 2017 JMP FINANCIAL SERVICES AND REAL ESTATE CONFERENCE
PJT Partners Inc. June 22, 2017 JMP FINANCIAL SERVICES AND REAL ESTATE CONFERENCE Notices and Disclaimers Forward-Looking Statements This presentation may contain forward-looking statements within the
More information(NASDAQ: CORT) Corcept Therapeutics Inc. Bullish. Investment Highlights
(NASDAQ: CORT) Bullish Overview Recent Price $4.84 52 Week Range $1.47 - $4.49 1 Month Range $2.30 - $2.97 Avg Daily Volume 270080.0 PE Ratio 0.0 Earnings Per Share Year EPS 2015(E) $-0.479 Capitalization
More informationCMIC HOLDINGS Co., Ltd. Consolidated Financial Results
(Note) This translation is prepared and provided for readers' convenience only. In the event of any discrepancy between this translated document and the original Japanese document, the original document
More informationNEBOSH HSE. Training. Certificate in Process Safety Management. Trainer : Andrew Gibbins. 16 th - 20 th April,2018 Angola
Training www.fleming.events NITA Number: NITA/TRN/1236 NEBOSH HSE Certificate in Process Safety Management Trainer : Andrew Gibbins Globally recognised health, safety and environmental qualifications 16
More informationOperational Performance Data
Operational Performance Data The tables below provide information regarding the available operational results for the 3 months ended June 30, 2018, as well as the prior four quarterly reporting periods
More informationKPIs & KEIs for Success
The Smart Manager Series (#3) KPIs & KEIs for Success Key principles & Survival Kit Tools October 2018 Smart Pharma Consulting Table of Contents 1. Introduction p. 2 2. Definitions p. 3 3. How to choose
More informationHalf-year financial report June 30, 2016
French société anonyme governed by an executive board and a supervisory board with a share capital of 2,694,782.70 euros composed of 53,895,654 shares with a nominal value of 0.05 euros each. Registered
More informationCustomised matching for your business needs. HKTDC Business Matching advantage. What you get. Act NOW
Customised matching for your business needs HKTDC Business Matching is a customised matching service dedicated to help you find business partners and facilitate trade between Hong Kong and the world. HKTDC
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationHealth Care Practice Center
Health Care Practice Center Power your practice. 800.372.1033 bna.com/bloomberglaw Seamlessly integrated intelligence. Practice pages Navigate the nuances of health care law. Bloomberg Law s Health Care
More informationCross Country Healthcare acquires Advantage RN
Cross Country Healthcare acquires Advantage RN Forward Looking Statements This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future
More informationAd hoc announcement Inside information pursuant to Article 17 MAR Heidelberg Pharma AG plans capital measure to fund its ATAC development programs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
More informationCFO VISION Navigate your world November Washington, D.C.
CFO VISION 2014 Navigate your world November 19 21 Washington, D.C. M&A: What it takes to be an Advantaged Acquirer Steve Joiner AERS Partner Deloitte & Touche LLP Mark L. Sirower Principal, Monitor Deloitte
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM N-Q
Investment Company Act file number 811-07074 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT
More information2Q 18 Earnings Call Presentation. February 5, 2018
2Q 18 Earnings Call Presentation February 5, 2018 Agenda John Chiminski, Chairman & Chief Executive Officer 2Q 18 Highlights Matt Walsh, Executive VP & Chief Financial Officer Business Update by Segment
More informationHALOZYME REPORTS FIRST QUARTER 2018 RESULTS
Contacts: Jim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS FIRST QUARTER 2018 RESULTS -- Revenue of $30.9 Million Includes a 50
More informationOVERVIEW OF CONVERGENCE BLENDED FINANCE INFORMATION SESSION & NETWORKING BREAKFAST ZÜRICH, 28 TH AUGUST, 2018
OVERVIEW OF BLENDED FINANCE INFORMATION SESSION & NETWORKING BREAKFAST ZÜRICH, 28 TH AUGUST, 2018 WHAT IS? Convergence is the global network for blended finance. We generate blended finance data, intelligence,
More informationWaters Corporation Management Presentation. July 2018
Waters Corporation Management Presentation July 2018 Cautionary Statements This presentation may contain forward-looking statements regarding future results and events. For this purpose, any statements
More informationFinancing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.
Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.0, Prague Venture Valuation Mission Independent assessment and valuation of
More informationPinsent Masons in the UAE
Pinsent Masons in the UAE Pinsent Masons In the UAE Introduction Our UAE office, based in the heart of Dubai s financial district, combines local knowledge with an international experience to advise clients
More informationFull Proposal Application Form
ERA-NET: Aligning national/regionaltranslational cancer research programmes and activities TRANSCAN-2 Joint Transnational Call for Proposals 2014 (JTC 2014) co-funded by the European Commission/DG Research
More informationEnzon Reports Third Quarter 2010 Results
Enzon Reports Third Quarter 2010 Results -- Results reflect continued investment in innovative oncology pipeline and increased operating efficiencies -- BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE)
More informationIR Presentation template
1 MacroGenics, Inc. IR Presentation template Healthcare [SA, JA, sector] Sector Spring 2017 Senior Analyst: Austin Gasparini Junior Analysts: Donavon Young, Anuraag Gopaluni 2 Recommendation and Company
More informationAffinity and Partnership Marketing in UK Commercial Non-Life Insurance
Affinity and Partnership Marketing in UK Commercial Non-Life Insurance Report prospectus July 2015 1 Prospectus contents Page What is the research? What is the rationale? What methodology has been used?
More informationOTC YEARBOOK. Full-year sales data to end-2017 from DB6 Global OTC Database THE ESSENTIAL GUIDE IN TODAY S CHALLENGING MARKETS
THE ESSENTIAL GUIDE IN TODAY S CHALLENGING MARKETS Key features Consumer health trends & developments on a global, regional and country level, with individual chapters covering: Major OTC categories Company
More information2013 China Development Forum survey report. Choosing China: Insights from multinationals on the investment environment
2013 China Development Forum survey report Choosing China: Insights from multinationals on the investment environment Target growth markets Which three of these key markets would you invest in? Source:
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K/A CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d) OF
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest
More informationCYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)
More information21 - Pharmacy Services
21 - Pharmacy Services The role of Health Plan of Nevada s (HPN) Pharmacy Services is to evaluate and determine the appropriateness of quality drug therapy while maintaining and improving therapeutic outcomes.
More information